Dr. Kate Sasser is the Chief Scientific Officer of Tempus. Dr. Sasser brings over 20 years of experience in translational research and precision medicine in biological sciences across academia and the pharmaceutical and biotech industry. Prior to Tempus, she led the translational research, precision medicine, and R&D operations organizations within Genmab, a biotech company focused on developing transformative antibody therapeutics as medicine. She also led translational research for oncology at Johnson and Johnson (Janssen PRD), using translational and data science approaches to accelerate clinical development. Dr. Sasser graduated from Oregon State University with a BS in Microbiology and received her PhD in integrated biomedical sciences from Ohio State University.